|Bid||33.99 x 300|
|Ask||34.04 x 1000|
|Day's Range||33.97 - 34.21|
|52 Week Range||29.83 - 37.39|
|PE Ratio (TTM)||28.65|
|Dividend & Yield||1.28 (3.75%)|
|1y Target Est||N/A|
On June 14, 2017, Pfizer (PFE) announced an agreement with Basilea Pharmaceutica for exclusive commercial rights for Cresemba in Europe.
After spending much of the last two months in a slow decline, shares of Pfizer have broken out of their downtrend.
On June 16, 2017, Pfizer announced detailed results from its ORAL (Oral Rheumatoid Arthritis TriaL) Strategy.